Max Herrmann

Max Herrmann

No open positions remaining

Net worth: 36 589 $ as of 31/05/2026

Finance
Health Technology
Commercial Services

Profile

Mr. Max Herrmann was previously employed as an Analyst by Stifel Nicolaus Europe Ltd., an Analyst by Oriel Securities Ltd., a Chief Financial Officer & Secretary by Silence Therapeutics Plc, a Chief Financial Officer by Regenerative Medicine Assets Ltd., a Research Analyst by ING Bank NV (United Kingdom), a Managing Director & Head-European Pharmaceutical by ING Groep NV, and a Financial Controller by Onyx Pharmaceuticals, Inc. He also served on the board at Axordia Ltd., Intercytex Ltd. and Regenerative Medicine Assets Ltd. He received his undergraduate degree from the University of Kent.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
0.01%
01/12/2025 58,000 ( 0.01% ) 36 589 $ 31/05/2026

Former positions of Max Herrmann

CompaniesPositionEnd
Analyst-Equity 01/07/2024
Analyst-Equity 01/02/2015
Director/Board Member 18/04/2013
SILENCE THERAPEUTICS PLC Director of Finance/CFO 02/08/2012
Analyst-Equity 01/06/2007
See the detail of Max Herrmann's experience

Training of Max Herrmann

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

81

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Finance

Finance

Health Technology

Commercial Services

Health Technology

Finance

Commercial Services

Consumer Services

Finance

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!